bitopertin [RO4917838]

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Schizophrenia

Phase 2

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

CompletedNCT01234779

Hoffmann-La RocheSchizophrenia

Start: 2011-02-28End: 2012-09-30Updated: 2016-11-02

Phase 3

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

CompletedNCT01192906

Hoffmann-La RocheSchizophrenia

Start: 2010-12-31End: 2014-07-31Updated: 2016-11-02

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

CompletedNCT01235585

Hoffmann-La RocheSchizophrenia

Start: 2010-12-31End: 2014-09-30Updated: 2016-11-02

Related Papers

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.

2016-11-0276 citations